Search

Your search keyword '"Kuci, Zyrafete"' showing total 23 results
Start Over Author "Kuci, Zyrafete"
23 results on '"Kuci, Zyrafete"'

1. Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

Author

Bonig, Halvard, Verbeek, Mareike, Herhaus, Peter, Braitsch, Krischan, Beutel, Gernot, Schmid, Christoph, Müller, Nadine, Bug, Gesine, Döring, Michaela, von Stackelberg, Arend, Tischer, Johanna, Ayuk, Francis, Wulf, Gerald, Holtick, Udo, Pfeffermann, Lisa‑Marie, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Kuci, Selim, Kuci, Zyrafete, Zens, Anke, Tribanek, Michael, Zeiser, Robert, Huenecke, Sabine, and Bader, Peter

Published
2024
Full Text
View/download PDF

2. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Author

Bonig, Halvard, Verbeek, Mareike, Herhaus, Peter, Braitsch, Krischan, Beutel, Gernot, Schmid, Christoph, Müller, Nadine, Bug, Gesine, Döring, Michaela, von Stackelberg, Arend, Tischer, Johanna, Ayuk, Francis, Wulf, Gerald, Holtick, Udo, Pfeffermann, Lisa-Marie, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Kuci, Selim, Kuci, Zyrafete, Zens, Anke, Tribanek, Michael, Zeiser, Robert, Huenecke, Sabine, and Bader, Peter

Published
2023
Full Text
View/download PDF

3. Sars-Cov-2 Fails to Infect Mesenchymal Stromal Cells (MSCs) - Pre-Clinical Investigations in Support of Therapeutic Use of MSCs for Severe COVID-19

Author

Pfeffermann, Lisa-Marie, primary, Bojkova, Denisa, additional, Kandler, Joshua, additional, Huenecke, Sabine, additional, Bremm, Melanie, additional, Piede, Natascha, additional, Kuci, Selim, additional, Kuci, Zyrafete, additional, Harenkamp, Sabine, additional, Bonig, Halvard, additional, and Bader, Peter, additional

Published
2022
Full Text
View/download PDF

7. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation MSC-FFM-Outcome Report of 92 Patients

Author

Bonig, Halvard, Kuci, Zyrafete, Kuci, Selim, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Mike, Greil, Johann, Barta, Aniko, Kallay, Krisztian M., Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene Teichert, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Phil, Alsultan, Abdulrahman, Buechner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Paneesha, Shankara, Novitzky-Basso, Igor, Gefen, Aharon, Nevo, Neta, Beutel, Gernot, Schlegel, Paul-Gerhardt, Klingebiel, Thomas, Bader, Peter, Bonig, Halvard, Kuci, Zyrafete, Kuci, Selim, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Mike, Greil, Johann, Barta, Aniko, Kallay, Krisztian M., Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene Teichert, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Phil, Alsultan, Abdulrahman, Buechner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Paneesha, Shankara, Novitzky-Basso, Igor, Gefen, Aharon, Nevo, Neta, Beutel, Gernot, Schlegel, Paul-Gerhardt, Klingebiel, Thomas, and Bader, Peter

Abstract

(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD >=degrees III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus >= 2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD.

Published
2019

8. Effective treatment and low mortality in patients with therapy-refractory aGvHD after treatment with MSC : post-approval observational data from 69 consecutive patients treated with 'MSC-FFM'

Author

Bader, Peter, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kállay, Kristián, Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Teichert-Luettichau, Irene, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkins, Philip, Alsultan, Abdulrahman, Buechner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann, Emilia, Hutter, Martin, Schäfer, Richard, Seifried, Erhard, Klingebiel, Thomas, Boenig, Halvard, and Kuci, Selim

Subjects
Medizin
Published
2018

9. Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients

Author

Bader, Peter, primary, Kuci, Selim, additional, Kuci, Zyrafete, additional, Bakhtiar, Shahrzad, additional, Basu, Oliver, additional, Bug, Gesine, additional, Dennis, Michael, additional, Greil, Johann, additional, Barta, Aniko, additional, Kallay, Krisztián, additional, Lang, Peter, additional, Lucchini, Giovanna, additional, Pol, Raj, additional, Schulz, Ansgar, additional, Sykora, Karl-Walter, additional, Teichert von Luettichau, Irene, additional, Herter-Sprie, Grit, additional, Uddin, Mohammad Ashab, additional, Jenkin, Philip, additional, Alsultan, Abdulrahman, additional, Büchner, Jochen, additional, Stein, Jerry, additional, Kelemen, Agnes, additional, Jarisch, Andrea, additional, Soerensen, Jan, additional, Salzmann-Manrique, Emilia, additional, Hutter, Martin, additional, Schaefer, Richard, additional, Seifried, Erhard, additional, Paneesha, Shankara, additional, Novitzky-Basso, Igor, additional, Gefen, Aharon, additional, Nevo, Neta, additional, Beutel, Gernot, additional, Schlegel, Paul G., additional, Klingebiel, Thomas, additional, and Bonig, Halvard, additional

Published
2018
Full Text
View/download PDF

10. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)

Author

Bader, Peter, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kallay, Krisztian M., Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Phil, Alsultan, Abdulrahman, Buechner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Klingebiel, Thomas, Bonig, Halvard, Kuci, Selim, Bader, Peter, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kallay, Krisztian M., Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Phil, Alsultan, Abdulrahman, Buechner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Klingebiel, Thomas, Bonig, Halvard, and Kuci, Selim

Abstract

The inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes of patients with aGvHD receiving MSC products. We developed a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses, referred to as MSC-Frankfurt am Main (MSC-FFM). Herein, we report outcomes of the 69 patients who have received MSC-FFM. These were 51 children and 18 adults with refractory aGvHD grade II (4%), III (36%) or IV (59%). Patients were refractory either to frontline therapy (steroids) (29%) or to steroids and 1-5 additional lines of immunosuppressants (71%) were given infusions in four weekly intervals. The day 28 overall response rate was 83%; at the last follow-up, 61% and 25% of patients were in complete or partial remission. The median follow-up was 8.1 months. Six-month estimate for cumulative incidence of non-relapse mortality was 27% (range, 16-38); leukemia relapse mortality was 2% (range, 0-5). This was associated with a superior six-month overall survival (OS) probability rate of 71% (range, 61-83), compared to the outcome of patients not treated with MSC-FFM. This novel product was effective in children and adults, suggesting that MSC-FFM represents a promising therapy for steroid refractory aGvHD.

Published
2018

11. Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation MSC-FFM: Treatment Results for 92 Consecutive Patients

Author

Bader, Peter, Kuci, Selim, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kallay, Krisztian, Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene Teichert, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Philip, Alsultan, Abdulrahman, Buchner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Paneesha, Shankara, Novitzky-Basso, Igor, Gefen, Aharon, Nevo, Neta, Beutel, Gernot, Schlegel, Paul G., Klingebiel, Thomas, Bonig, Halvard, Bader, Peter, Kuci, Selim, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kallay, Krisztian, Lang, Peter, Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl-Walter, von Luettichau, Irene Teichert, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Philip, Alsultan, Abdulrahman, Buchner, Jochen, Stein, Jerry, Kelemen, Agnes, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Hutter, Martin, Schaefer, Richard, Seifried, Erhard, Paneesha, Shankara, Novitzky-Basso, Igor, Gefen, Aharon, Nevo, Neta, Beutel, Gernot, Schlegel, Paul G., Klingebiel, Thomas, and Bonig, Halvard

Published
2018

12. Excellent response, low TRM and good survival in patients with therapy-refractory aGvHD after treatment with potency-defined doses of MSCs generated from a serum-free MSC-BANK of pooled BM-MNCS from multiple healthy donors

Author

Bader, Peter, primary, Kuci, Zyrafete, additional, Bakhtiar, Shahrzad, additional, Basu, Oliver, additional, Bug, Gesine, additional, Dennis, Mike, additional, Greil, Johann, additional, Kallay, Krisztian M., additional, Lang, Peter, additional, Luccini, Giovanna, additional, Pol, Raj, additional, Schulz, Ansgar, additional, Sykora, Karl- Walther, additional, von Luettichau, Irene, additional, Jarisch, Andrea, additional, Soerensen, Jan, additional, Salzmann, Emilia, additional, Seifried, Erhard, additional, Klingebiel, Thomas, additional, Boenig, Halvard B., additional, and Kuci, Selim, additional

Published
2017
Full Text
View/download PDF

13. Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Author

Bader, Peter, Verbeek, Mareike, Herhaus, Peter, Pachzelt, Lavinia, Beutel, Gernot, Schmid, Christoph, Müller, Nadine, Bug, Gesine, von Stackelberg, Arend, Tischer, Johanna, Ayuk, Francis A., Wulf, Gerald G., Pfeffermann, Lisa-Marie, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Kuci, Selim, Kuci, Zyrafete, Zens, Anke, Tribanek, Michael, Zeiser, Robert, Huenecke, Sabine, and Bonig, Halvard

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

14. Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product “MSC-Ffm” Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Author

Bader, Peter, Kuci, Selim, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Michael, Greil, Johann, Barta, Aniko, Kallay, Krisztián, Lang, Peter J., Lucchini, Giovanna, Pol, Raj, Schulz, Ansgar S., Sykora, Karl-Walter, Teichert von Luettichau, Irene, Herter-Sprie, Grit, Uddin, Mohammad Ashab, Jenkin, Philip, Alsultan, Abdulrahman S., Büchner, Jochen, Stein, Jerry, Kelemen, Agnes, Paneesha, Shankaranarayana, Jarisch, Andrea, Soerensen, Jan, Salzmann-Manrique, Emilia, Seifried, Erhard, Klingebiel, Thomas, and Bonig, Halvard

Published
2017
Full Text
View/download PDF

15. Establishment of a GMP-compliant mesenchymal stromal cell bank from pooled bone marrow mononuclear cells of eight “third-party” healthy donors: clinical evidence of safety and efficacy

Author

Kuci, Zyrafete, primary, Bönig, Halvard, additional, Kreyenberg, Hermann, additional, Bunos, Milica, additional, Jauch, Anna, additional, Janssen, Johannes, additional, Skific, Marijana, additional, Michel, Kristina, additional, Eising, Ben, additional, Lucchini, Giovanna, additional, Jarisch, Andrea, additional, Soerensen, Jan, additional, Seifried, Erhard, additional, Klingebiel, Thomas, additional, Bader, Peter, additional, and Kuci, Selim, additional

Published
2015
Full Text
View/download PDF

17. LB12 - Excellent response, low TRM and good survival in patients with therapy-refractory aGvHD after treatment with potency-defined doses of MSCs generated from a serum-free MSC-BANK of pooled BM-MNCS from multiple healthy donors

Author

Bader, Peter, Kuci, Zyrafete, Bakhtiar, Shahrzad, Basu, Oliver, Bug, Gesine, Dennis, Mike, Greil, Johann, Kallay, Krisztian M., Lang, Peter, Luccini, Giovanna, Pol, Raj, Schulz, Ansgar, Sykora, Karl- Walther, von Luettichau, Irene, Jarisch, Andrea, Soerensen, Jan, Salzmann, Emilia, Seifried, Erhard, Klingebiel, Thomas, Boenig, Halvard B., and Kuci, Selim

Published
2017
Full Text
View/download PDF

18. Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases

Author

Wernicke, Caroline M, primary, Grunewald, Thomas GP, additional, Hendrik, Juenger, additional, Kuci, Selim, additional, Kuci, Zyrafete, additional, Koehl, Ulrike, additional, Mueller, Ingo, additional, Doering, Michaela, additional, Peters, Christina, additional, Lawitschka, Anita, additional, Kolb, Hans-Jochem, additional, Bader, Peter, additional, Burdach, Stefan, additional, and von Luettichau, Irene, additional

Published
2011
Full Text
View/download PDF

20. Phenotypic and Functional Characterization of Mesenchymal Stromal Cells Derived from CD271+- Bone Marrow Mononuclear Cells and Mesenchymal Stromal Cells Derived through Plastic Adherence.

Author

Kuci, Selim, primary, Puetsch, Kathrin, primary, Kuci, Zyrafete, primary, Huenecke, Sabine, primary, Kreyenberg, Hermann, primary, Amara, Chandra Sekhar, primary, Piechaczek, Christoph, primary, Koehl, Ulrike, primary, Klingebiel, Thomas, primary, and Bader, Peter, primary

Published
2007
Full Text
View/download PDF

23. The Phenotype and Functional Activity of Mesenchymal Stromal Cells in Pediatric Patients with Non-Malignant Hematological Diseases.

Author

Kuci Z, Jordan C, Wehner S, Sörensen J, Jarisch A, Salzmann-Manrique E, Pfeffermann LM, Klingebiel T, Bader P, and Kuҫi S

Subjects
Adipocytes cytology, Adipocytes metabolism, Adolescent, Anemia, Sickle Cell metabolism, CD146 Antigen metabolism, Case-Control Studies, Cell Differentiation drug effects, Cell Lineage, Cell Proliferation drug effects, Child, Child, Preschool, Chondrocytes cytology, Chondrocytes metabolism, Dinoprostone metabolism, Female, Humans, Indomethacin pharmacology, Male, Mesenchymal Stem Cells cytology, Osteoblasts cytology, Osteoblasts metabolism, Phenotype, beta-Thalassemia metabolism, Anemia, Sickle Cell pathology, Mesenchymal Stem Cells metabolism, beta-Thalassemia pathology
Abstract

As the biology of mesenchymal stromal cells (MSCs) in patients with non-malignant hematological diseases (NMHD) is poorly understood, in the current study we performed a basic characterization of the phenotype and functional activity of NMHD-MSCs. Bone marrow (BM) of patients with thalassemia major (TM) possessed a significantly higher number of nucleated cells (BM-MNCs)/mL BM than healthy donors ( P < 0.0001), which however did not result in a higher number of colony forming units-fibroblast (CFU-F) per milliliter BM. In contrast, from 1 × 10 6 BM-MNCs of patients with sickle cell disease (SCD) were generated significantly more CFU-Fs than from TM-BM-MNCs ( P < 0.013) and control group ( P < 0.02). In addition, NMHD-MSCs expressed significantly lower levels of CD146 molecule, demonstrated an equal proliferation potential and differentiated along three lineages (osteoblasts, chondrocytes and adipocytes) as healthy donors' MSCs, with exception of TM-MSCs which differentiated weakly in adipocytes. In contrast to other NMHD-MSCs and healthy donors' MSCs, TM-MSCs demonstrated an impaired in vitro immunosuppressive potential, either. Noteworthy, the majority of the immunosuppressive effect of NMHD-MSCs was mediated through prostaglandin-E2 (PGE2), because indomethacin (an inhibitor of PGE2 synthesis) was able to significantly reverse this effect. Our results indicate therefore that NMHD-MSCs, except TM-MSCs, may be used as an autologous cell-based therapy for post-transplant complications such as graft failure, graft-versus-host disease (GvHD) and osteonecrosis., Competing Interests: The authors declare no competing interests.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results